HomeQuestion
Would you consider adjuvant capecitabine as well as trastuzumab in a patient with ER/PR negative, HER2 positive breast cancer treated with neoadjuvant chemotherapy /trastuzumab/pertuzumab who has residual disease on path?
1 Answers
Mednet Member
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Treatment with adjuvant TDM1 would be the recommended approach based on the KATHERINE data.